Trulicity (Dulaglutide) for Weight Loss: FDA Label, Evidence, and How It Compares to Wegovy/Ozempic (2026)

Trulicity (dulaglutide, Eli Lilly) is the “older sibling” once-weekly GLP-1 — FDA-approved September 2014 for type 2 diabetes glycemic control and, since 2020, for major adverse cardiovascular event (MACE) reduction in adults with T2D and either established CVD or multiple CV risk factors (REWIND, Lancet 2019, PMID 31189511 — 12% relative risk reduction). It is NOT FDA-approved for chronic weight management. Off-label, AWARD-11 (Diabetes Care 2021, PMID 33397768) showed dulaglutide 4.5 mg produced -4.6 kg weight loss at 36 weeks vs -3.0 kg on the 1.5 mg dose (ETD -1.6 kg, p<0.001). That magnitude is meaningfully smaller than Wegovy 2.4 mg (~14.9% at 68 weeks per STEP-1) or Zepbound 15 mg (~20.9% at 72 weeks per SURMOUNT-1). For patients whose primary goal is weight loss, Trulicity is not first-line. For patients whose primary indication is T2D — especially with established CV risk — Trulicity remains a reasonable, well-evidenced once-weekly option with a 10+ year post-marketing safety record.

What is Trulicity?

Trulicity is the brand name Eli Lilly markets dulaglutide under in the United States. Dulaglutide is a long-acting once-weekly GLP-1 receptor agonist administered as a subcutaneous injection. It was FDA-approved on September 18, 2014 under BLA 125469 for the treatment of adults with type 2 diabetes mellitus.

Mechanically, dulaglutide is a recombinant fusion protein — two molecules of a modified human GLP-1 fragment covalently linked to a modified human IgG4 Fc heavy chain. The Fc fusion confers a dramatically extended half-life (~5 days) relative to native GLP-1 (which has a half-life of ~2 minutes), enabling once-weekly subcutaneous dosing. The Fc fusion is also why dulaglutide is regulated as a biologic (Biologics License Application pathway, 351(a) of the Public Health Service Act) rather than as a small-molecule drug under the New Drug Application pathway. This regulatory framing has direct downstream consequences for post-loss-of-exclusivity competition (see the biosimilar timeline section below).

Is Trulicity a GLP-1?

Yes. Trulicity (dulaglutide) is a glucagon- like peptide-1 (GLP-1) receptor agonist. It binds and activates the GLP-1 receptor on pancreatic beta cells (and on other cell types throughout the body), driving the same downstream effects as endogenous GLP-1: glucose-dependent insulin secretion, suppressed glucagon release, slowed gastric emptying, and central appetite reduction.

The GLP-1 receptor agonist drug class as currently FDA- approved in the United States includes (with primary indication):

• Trulicity (dulaglutide) — Eli Lilly, weekly injection, T2D + MACE reduction
• Ozempic (semaglutide) — Novo Nordisk, weekly injection, T2D + MACE reduction
• Wegovy (semaglutide) — Novo Nordisk, weekly injection / oral pill, chronic weight management + MACE reduction in adults with established CVD + obesity
• Rybelsus (oral semaglutide) — Novo Nordisk, daily oral tablet, T2D
• Victoza (liraglutide) — Novo Nordisk, daily injection, T2D (generic available since Dec 2024)
• Saxenda (liraglutide 3 mg) — Novo Nordisk, daily injection, chronic weight management (generic available since Aug 2025)
• Foundayo (orforglipron) — Eli Lilly, daily oral tablet, chronic weight management (FDA-approved April 2026, oral non-peptide GLP-1)
• Byetta / Bydureon (exenatide) — AstraZeneca, twice-daily / weekly injection, T2D (Bydureon discontinued in some markets)

Mounjaro and Zepbound (tirzepatide) are sometimes grouped with the GLP-1 class, but tirzepatide is a dual GIP / GLP-1 receptor agonist — it agonizes both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. The dual mechanism is thought to contribute to its higher weight-loss efficacy in head-to-head comparisons with semaglutide (SURPASS-2, NEJM 2021, PMID 34170647 for T2D; SURMOUNT-5 for weight management). Trulicity is a pure GLP-1 receptor agonist with no GIP activity.

FDA-approved indications (verbatim from §1)

Per the Trulicity DailyMed label §1 INDICATIONS AND USAGE, Trulicity is indicated for two distinct uses:

“TRULICITY is indicated:
• as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
• to reduce the risk of major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.”

Notice what is not on this list: chronic weight management. Trulicity is not FDA-approved for weight loss. The drugs that are: Wegovy, Zepbound, Saxenda, Foundayo. For patients without type 2 diabetes whose primary goal is weight loss, Trulicity is off-label — and insurance plans treat it accordingly.

Trulicity for weight loss: the evidence

Trulicity does produce weight loss as a secondary effect of its GLP-1 receptor agonism — but the magnitude is smaller than what modern weight-management-indicated GLP-1s deliver, and the studied populations were T2D patients, not non-diabetic patients with obesity.

AWARD-11 — the highest-dose dulaglutide weight-loss data (PMID 33397768)

AWARD-11 (Frias et al., Diabetes Care 2021) is the closest thing to a weight-loss-focused dulaglutide trial we have. It was a 36-week (with 52-week extension) randomized, double- blind, parallel-arm trial in 1,842 metformin-treated T2D patients comparing escalation from dulaglutide 1.5 mg to 3.0 mg or 4.5 mg once weekly. It is the trial that supported the FDA approval of the dulaglutide 3.0 mg and 4.5 mg dose strengths (added to the label in September 2020).

Verbatim primary weight findings at the 36-week primary endpoint:

• Dulaglutide 4.5 mg vs 1.5 mg (treatment-regimen estimand): -4.6 kg vs -3.0 kg, ETD -1.6 kg, p<0.001
• Dulaglutide 4.5 mg vs 1.5 mg (efficacy estimand): -4.7 kg vs -3.1 kg, ETD -1.6 kg, p<0.001
• Dulaglutide 3.0 mg fell between the 1.5 mg and 4.5 mg arms on both weight and HbA1c reduction — supporting a monotonic dose-response relationship.

The verbatim conclusion: “In patients with type 2 diabetes inadequately controlled by metformin, escalation from dulaglutide 1.5 mg to 3.0 mg or 4.5 mg provided clinically relevant, dose-related reductions in HbA1c and body weight with a similar safety profile.”

For context: -4.6 kg in a T2D population at 36 weeks on the highest dulaglutide dose is real but modest. STEP-1 (Wilding et al., NEJM 2021, PMID 33567185) reported semaglutide 2.4 mg producing -14.9% mean body-weight reduction at 68 weeks (~15 kg in a 100-kg starting-weight population) — about 3-4× larger than dulaglutide 4.5 mg in AWARD-11. SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID 35658024) reported tirzepatide 15 mg producing -20.9% at 72 weeks — about 4-5× larger than dulaglutide 4.5 mg.

AWARD-1 — dulaglutide vs exenatide (PMID 24879836)

AWARD-1 (Wysham et al., Diabetes Care 2014) was the head-to- head trial of dulaglutide 1.5 mg or 0.75 mg once weekly vs exenatide 10 mcg twice daily (the older Byetta formulation) as add-on to metformin + pioglitazone in 976 T2D patients. Primary endpoint was HbA1c reduction at 26 weeks. Verbatim findings:

• HbA1c reduction at 26 weeks:
  • Dulaglutide 1.5 mg: -1.51%
  • Dulaglutide 0.75 mg: -1.30%
  • Exenatide 10 mcg BID: -0.99%
  • Placebo: -0.46%
• Both dulaglutide doses were superior to placebo and to exenatide at 26 and 52 weeks (p < 0.001 for all comparisons).
• Greater percentages of patients reached HbA1c targets with dulaglutide 1.5 mg and 0.75 mg than with placebo or exenatide.

AWARD-1 established dulaglutide as superior to exenatide BID on glycemic control. Weight loss was a secondary endpoint; differences between dulaglutide and exenatide were smaller and not the primary point of the trial. For our weight-loss question, AWARD-11 is the more relevant data.

AWARD-7 — dulaglutide in moderate-to-severe CKD (PMID 29910024)

AWARD-7 (Tuttle et al., Lancet Diabetes Endocrinol 2018) was the renal-population trial. 577 T2D patients with moderate- to-severe chronic kidney disease (eGFR 15-59 mL/min/1.73 m ²) were randomized to dulaglutide 0.75 mg or 1.5 mg once weekly vs insulin glargine titrated to glycemic targets. Verbatim findings:

• HbA1c reduction at 26 weeks: Dulaglutide 1.5 mg, 0.75 mg, and insulin glargine all achieved approximately -1.1 to -1.2% reductions. Dulaglutide 1.5 mg and 0.75 mg met non-inferiority criteria vs insulin glargine.
• Renal function preservation: at 52 weeks, eGFR was higher in the dulaglutide groups vs insulin glargine. The benefit was particularly relevant in the macroalbuminuria subgroup.
• Hypoglycemia: dulaglutide groups had lower rates of symptomatic hypoglycemia than the insulin glargine arm.

AWARD-7 is the trial that supported dulaglutide use in moderate-to-severe CKD without dose adjustment. It is not a weight-loss trial, but the renal-protection signal makes Trulicity a reasonable choice for T2D + CKD patients who also want some weight benefit.

Why Trulicity weight loss is lower than Wegovy / Zepbound

Three reasons the dulaglutide weight-loss ceiling is lower than what Wegovy or Zepbound achieve:

• Different molecular structure. Dulaglutide is a Fc-fusion biologic (~63 kDa) — much larger than semaglutide (~4 kDa, also peptide but no Fc fusion) or tirzepatide (~4.8 kDa, GIP/GLP-1 dual peptide). The Fc fusion was engineered to extend half-life and reduce immunogenicity, but it also alters tissue distribution and may reduce CNS penetration relative to the smaller peptides — which matters because central appetite suppression is a major contributor to weight loss in this drug class. This is mechanistic speculation; the head-to- head comparator data is what we anchor on.
• Lower dose ceiling. Trulicity tops out at 4.5 mg/week. Wegovy weight-management dosing is 2.4 mg/week (semaglutide is more potent on a per-mg basis). Zepbound tops out at 15 mg/week of tirzepatide. Foundayo tops out at 17.2 mg/day of orforglipron. The maximum approved dose of dulaglutide simply is not as high as the modern weight- management-indicated drugs need to be.
• The trial endpoints didn't target weight loss. The AWARD program was designed to support a T2D indication, not a weight-management indication. Trial populations were T2D patients (not patients with obesity BMI ≥30 without diabetes), the comparators were anti- diabetic drugs, primary endpoints were HbA1c, and trial durations were geared to glycemic outcome assessment, not to the longer 68-72 week timeframes that STEP / SURMOUNT used to establish weight-loss plateaus.

For patients whose primary clinical goal is weight loss, these three factors compound — and the published efficacy data simply do not support choosing Trulicity over Wegovy or Zepbound when weight loss is the priority and insurance is not the gating constraint.

Trulicity for cardiovascular disease — REWIND (PMID 31189511)

Where Trulicity has a uniquely strong evidence base is cardiovascular outcomes. REWIND (Gerstein et al., Lancet 2019) was the cardiovascular outcomes trial that supported the 2020 MACE-reduction labeling addition.

• Design: 9,901 T2D adults randomized to dulaglutide 1.5 mg/week vs placebo. Median follow-up 5.4 years.
• Population: T2D with either established cardiovascular disease (~31%) OR multiple CV risk factors (~69%). Mean age 66, mean baseline HbA1c 7.3%.
• Primary endpoint: composite of non-fatal MI, non-fatal stroke, or CV death.
• Result: 12.0% (dulaglutide) vs 13.4% (placebo) — HR 0.88, 95% CI 0.79-0.99, p = 0.026. Approximately 12% relative risk reduction in MACE.

REWIND was the first GLP-1 cardiovascular outcomes trial to demonstrate MACE benefit in a population that included a majority of patients without established CVD — prior CVOTs (LEADER for liraglutide, SUSTAIN-6 for semaglutide) had primarily enrolled established-CVD populations. The implication: dulaglutide's CV benefit appears to extend to T2D patients with risk factors but no prior CV event, expanding the addressable population.

For T2D patients with CV risk who also want a meaningful (if modest) weight benefit and who respond well to once-weekly dosing, Trulicity is a reasonable choice and is supported by a deeper outcomes-trial dataset than most alternatives.

Trulicity dosing schedule

Per the DailyMed label §2 DOSAGE AND ADMINISTRATION, Trulicity is dosed in 4 strengths once weekly by subcutaneous injection in the abdomen, thigh, or upper arm:

Verbatim §2 dosing instructions: dose escalations should occur no sooner than every 4 weeks. Trulicity is supplied as single-dose pens; missed doses can be taken if there are at least 3 days (72 hours) until the next scheduled dose, otherwise skipped.

For pediatric patients ages 10 and older with T2D, the starting dose is 0.75 mg once weekly. The pediatric T2D indication was added in June 2022 based on AWARD-PEDS.

Trulicity side effects (verbatim §6)

Per the DailyMed §6 ADVERSE REACTIONS section, the most common adverse reactions (incidence ≥5% on any dulaglutide dose AND more frequently than placebo) in pooled placebo- controlled trials include:

• Nausea — class-typical, peaks during dose initiation and escalation, usually resolves within weeks
• Diarrhea
• Vomiting
• Abdominal pain
• Decreased appetite — feature, not bug, of the GLP-1 mechanism
• Dyspepsia
• Fatigue

These are GLP-1 class-typical events and overlap closely with the Ozempic, Wegovy, Mounjaro, Zepbound, and Foundayo side-effect profiles. Dose escalation no sooner than every 4 weeks is the labeled mitigation strategy.

Less common but clinically important adverse events from §5 WARNINGS AND PRECAUTIONS:

• Boxed warning: thyroid C-cell tumors. Dulaglutide causes thyroid C-cell tumors in rats. Whether this risk extends to humans is unknown. Trulicity is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is a class-wide GLP-1 RA boxed warning.
• Pancreatitis — postmarketing reports of acute pancreatitis. Discontinue if suspected.
• Hypoglycemia when used with insulin or sulfonylureas. Dose reduction of insulin / sulfonylurea may be needed.
• Acute kidney injury — case reports linked to volume depletion from GI side effects (nausea, vomiting, diarrhea).
• Hypersensitivity reactions — including anaphylaxis and angioedema. Discontinue and treat.
• Severe gastrointestinal disease — not recommended in patients with severe GI disease including gastroparesis (GLP-1s slow gastric emptying further).
• Diabetic retinopathy complications in patients with type 2 diabetes mellitus and a history of diabetic retinopathy — monitor.

Insurance coverage for Trulicity

Trulicity is on most major commercial and Medicare formularies because it is a T2D drug — and T2D drug coverage is much broader than chronic-weight-management drug coverage. This is the single most consequential difference between Trulicity and Wegovy / Zepbound for many patients.

• Commercial insurance: typically covered with prior authorization documenting T2D diagnosis (ICD-10 E11.x) and often a documented metformin trial (step therapy). PA approval rates for T2D GLP-1s tend to be significantly higher than for weight-management GLP-1s.
• Medicare Part D: Trulicity is covered on most Part D formularies. The Inflation Reduction Act $2,000 annual out-of-pocket cap applies starting 2025, which materially reduces patient cost-share for the most expensive tiers. Medicare does NOT cover GLP-1s for weight-management indications (this is a statutory exclusion that has not been repealed as of 2026-05-09).
• Medicaid: coverage varies by state. Trulicity is generally covered for T2D in most state Medicaid programs.
• Cash-pay retail: approximately $800-1,000/month for the 1.5 mg or higher pens at major retail pharmacies (verify current pricing at GoodRx before assuming). Lilly offers a Trulicity Savings Card for commercially insured patients with T2D coverage that can reduce out-of-pocket cost to as little as $25/month. The savings card is not available to Medicare or Medicaid beneficiaries.

For patients without insurance who would be paying cash, the relative price of Trulicity is roughly comparable to brand Ozempic and brand Wegovy. The major affordability advantage is on the prior-authorization side, not the cash-price side.

When Trulicity makes sense (the right patient profile)

• T2D patient with established CVD or multiple CV risk factors — REWIND's 12% MACE reduction is a real benefit, and the once-weekly dosing supports adherence.
• T2D patient with moderate-to-severe CKD (eGFR 15-59) — AWARD-7 supports use without dose adjustment, with renal-function preservation signal.
• T2D patient where insurance gates Wegovy / Zepbound — Trulicity coverage is far more reliable on T2D formularies than Wegovy / Zepbound coverage on weight-management formularies. The path of least resistance to a once-weekly GLP-1 in many commercial plans is Trulicity (or Ozempic or Mounjaro), not Wegovy or Zepbound.
• T2D patient who values long real-world safety experience — Trulicity has 11+ years of post- marketing surveillance (FDA-approved Sept 2014). Wegovy has 5 years. Zepbound has 3 years. Foundayo has just over 1 month. For patients who weight historical safety experience heavily, Trulicity is the most-studied modern weekly GLP-1.
• T2D patient who would benefit from modest weight loss — -4.6 kg at 4.5 mg in AWARD-11 is real and clinically relevant for the cardiometabolic improvement stack, even if it's not what a primarily-obesity patient would choose.

When Trulicity is NOT first-line

• Patient's primary goal is weight loss and they do not have type 2 diabetes — Trulicity is off- label, insurance will typically deny it under non-T2D coverage logic, and the published weight-loss magnitude is 3-5× lower than what Wegovy or Zepbound deliver. Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide 15 mg), or Foundayo (orforglipron 17.2 mg) are first-line.
• T2D + obesity where weight loss is the dominant clinical concern — Mounjaro (tirzepatide for T2D) delivers far more weight loss than Trulicity, has a similar MACE-supportive label expansion, and has better glycemic outcomes. Most prescribers in 2026 default to Mounjaro for this profile. See our Wegovy vs Mounjaro decision guide for the molecule-vs-indication framing.
• Patient who prefers an oral pill — Rybelsus (oral semaglutide) for T2D, or Foundayo (oral orforglipron) for weight management, are the oral alternatives. Trulicity is injection-only.
• Pregnancy or planning pregnancy — like every GLP-1 RA, Trulicity is not recommended during pregnancy. The label advises discontinuation 2 months before a planned pregnancy because of the long (~5 day) half-life — the effective washout window is longer than Saxenda's but shorter than Wegovy / Ozempic (semaglutide ~1 week half-life). See our GLP-1 pregnancy / PCOS / fertility guide for the cross-class washout discussion.
• History of medullary thyroid carcinoma or MEN 2 — Trulicity is contraindicated. Class-wide contraindication for all GLP-1 RAs.
• Severe gastroparesis or other severe GI disease — not recommended per §5.

Generic Trulicity / biosimilar timeline

Because Trulicity is a Fc-fusion biologic regulated under the BLA pathway (351(a) of the Public Health Service Act), post-loss-of-exclusivity competition would come via biosimilars through the 351(k) abbreviated pathway — not via small-molecule generics through the Hatch-Waxman ANDA pathway. This is the same regulatory framework as monoclonal antibody biologics (Humira, Remicade, etc.), and it has direct downstream consequences:

• Biosimilars are NOT identical to the originator. They are “highly similar” with no clinically meaningful differences in safety, purity, or potency. They require their own development program — not just analytical characterization.
• Biosimilar approval requires extensive analytical + clinical bridging data — typically a Phase 1 PK study and at least one Phase 3 confirmatory study. Total development cost is generally 5-10× higher than a small-molecule generic.
• Interchangeability is a separate FDA designation. Without it, pharmacists cannot substitute biosimilar for originator without prescriber permission in most states.
• As of 2026-05-09, no Trulicity biosimilar has been FDA-approved. The first generic GLP-1 RAs approved in the US (Hikma generic liraglutide / Victoza Dec 2024; Teva generic liraglutide 3 mg / Saxenda Aug 2025) are small-molecule peptides regulated under the NDA pathway and therefore are generics, not biosimilars — so they don't bear on the dulaglutide timeline. Eli Lilly's composition-of-matter and dosing-regimen patents on dulaglutide extend for several more years (verify current Orange Book / Purple Book status). For the sister-class patent-cliff tracker covering Wegovy, Ozempic, Mounjaro, Zepbound, see our GLP-1 patent-cliff tracker.

Bottom line

Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist FDA-approved for T2D and for MACE reduction in T2D patients with CV risk — not for chronic weight management. Its weight-loss effect is real but modest: -4.6 kg at the 4.5 mg max dose at 36 weeks per AWARD-11 (PMID 33397768), roughly 3-5× smaller than what Wegovy 2.4 mg or Zepbound 15 mg deliver. Where Trulicity excels is the T2D + CV risk space (REWIND, PMID 31189511 — 12% MACE reduction, HR 0.88) and the T2D + CKD space (AWARD-7, PMID 29910024 — renal-function preservation). Insurance coverage on T2D formularies is much broader than weight-management coverage, and 11+ years of post-marketing safety surveillance is the deepest in the modern weekly GLP-1 class. As a Fc-fusion biologic regulated under the BLA pathway, Trulicity faces biosimilar — not generic — post-LOE competition, and no biosimilar has been FDA-approved as of mid-2026. For patients whose primary clinical goal is type 2 diabetes management with a meaningful CV-risk dataset behind it, Trulicity remains a reasonable choice. For patients whose primary goal is weight loss, Wegovy, Zepbound, or Foundayo are first-line — talk to your prescriber about which fits your clinical situation and your insurance coverage.

Related research

• Type 2 diabetes vs weight loss GLP-1 disambiguation — which brands are which indication
• Wegovy vs Mounjaro: different molecules, different indications
• SGLT2 inhibitors vs GLP-1 RAs (Jardiance, Farxiga, Ozempic, Trulicity) — when to use each
• Best FDA-approved appetite suppressant 2026 — full comparison
• GLP-1 patent-cliff tracker — when each goes generic / biosimilar
• GLP-1 medications pillar — every approved + investigational agent
• FDA-approved weight-loss medications hub